ReviewInternational journal of nanomedicine2014
Nanopharmaceuticals (part 1): products on the market.
Review in International journal of nanomedicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 159 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
159 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Nanomedicinal products: a survey on specific toxicity and side effects.International journal of nanomedicine · 2017Pooled it
- Everolimus Delivery via Lignin Nanoparticles Enhances Antitumor Activity in Hormone Receptor-Positive Breast Cancer.Precision chemistry · 2026Article
- Intraorgan and targeted nanodelivery in organ transplantation of nonhuman primates.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026Article
- Nanoparticles: An Emerging Hope in Cancer Therapy.Nanomaterials (Basel, Switzerland) · 2026Review
- Voriconazole nanosuspension-loaded ocular bilayer dissolving microneedle patch for the management of fungal keratitis.Drug delivery and translational research · 2026Article
- Fabrication techniques and biomedical applications of strontium-based nanofibers.Journal of nanobiotechnology · 2026Review
- Monosialoganglioside-Containing Nanoliposomes Protect Against Acute and Chronic Ischemic Stroke Injury.Journal of the American Heart Association · 2026Article
- Albumin Nanoparticles as Multifunctional Carriers for Advanced Therapeutics.Pharmaceutics · 2026Review
- Inhibition of craniosynostosis and premature suture fusion inScience advances · 2025Article
- Nanotherapy for Neural Retinal Regeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Acid-cleavable poly(oxazoline) surfactants.Polymer chemistry · 2025Article
- Temperature- and pH-Responsive Poly(NIPAM-Gels (Basel, Switzerland) · 2025Article
- Comprehensive insights into glioblastoma multiforme: drug delivery challenges and multimodal treatment strategies.Therapeutic delivery · 2025Review
- Recent Advancements in Nanopharmaceuticals for Novel Drug Delivery Systems.Pharmaceutical nanotechnology · 2025Review
- Advancements in Nanomedicine for the Diagnosis and Treatment of Kidney Stones.International journal of nanomedicine · 2025Review
- Advanced Drug Delivery Systems: From Microsponges to Nanotechnologies.Recent advances in inflammation & allergy drug discovery · 2025Article
- Nanomaterial-enabled drug transport systems: a comprehensive exploration of current developments and future avenues in therapeutic delivery.3 Biotech · 2024Review
- From lab to industrial development of lipid nanocarriers using quality by design approach.International journal of pharmaceutics: X · 2024Review
- Future-Oriented Nanosystems Composed of Polyamidoamine Dendrimer and Biodegradable Polymers as an Anticancer Drug Carrier for Potential Targeted Treatment.Pharmaceutics · 2024Article
- Synthesis and evaluation of nanosized aluminum MOF encapsulating Umbelliferon: assessing antioxidant, anti-inflammatory, and wound healing potential in an earthworm model.BMC biotechnology · 2024Article
99 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2000, the National Institute of Health launched the National Nanotechnology Initiative to support, coordinate, and advance research and development of nanoscale projects. The impact of this new program on health-science related research and development became quickly visible. Broad governmental financial support advanced the start of new, and the deepening of already existing, interdisciplinary research. The anticipated merger of nanoscience with medicine quickly instigated the conceptualization of nanomedicine. The adoption of nanoscience terminology by pharmaceutical scientists resulted in the advent of nanopharmaceuticals. The term "nano" became tantamount to "cutting-edge" and was quickly embraced by the pharmaceutical science community. Colloidal drug delivery systems reemerged as nanodrug delivery systems; colloidal gold became a suspension of nano gold particles. In this review, we first review nanoscience related definitions applied to pharmaceuticals, we then discuss all 43 currently approved drug formulations which are publicized as nanopharmaceuticals, and finally we analyze clinical aspects of selected drug formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.